SG11201804836RA - Treatment of fibrosis - Google Patents

Treatment of fibrosis

Info

Publication number
SG11201804836RA
SG11201804836RA SG11201804836RA SG11201804836RA SG11201804836RA SG 11201804836R A SG11201804836R A SG 11201804836RA SG 11201804836R A SG11201804836R A SG 11201804836RA SG 11201804836R A SG11201804836R A SG 11201804836RA SG 11201804836R A SG11201804836R A SG 11201804836RA
Authority
SG
Singapore
Prior art keywords
international
singapore
rule
london
pct
Prior art date
Application number
SG11201804836RA
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Original Assignee
Singapore Health Serv Pte Ltd
Nat Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55274842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201804836R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Singapore Health Serv Pte Ltd, Nat Univ Singapore filed Critical Singapore Health Serv Pte Ltd
Publication of SG11201804836RA publication Critical patent/SG11201804836RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201804836RA 2015-12-16 2016-12-16 Treatment of fibrosis SG11201804836RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1522186.4A GB201522186D0 (en) 2015-12-16 2015-12-16 Treatment of fibrosis
PCT/EP2016/081430 WO2017103108A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis

Publications (1)

Publication Number Publication Date
SG11201804836RA true SG11201804836RA (en) 2018-07-30

Family

ID=55274842

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201804836RA SG11201804836RA (en) 2015-12-16 2016-12-16 Treatment of fibrosis
SG10201908380T SG10201908380TA (en) 2015-12-16 2016-12-16 Treatment of fibrosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201908380T SG10201908380TA (en) 2015-12-16 2016-12-16 Treatment of fibrosis

Country Status (23)

Country Link
US (15) US10035852B2 (ko)
EP (7) EP3431498A1 (ko)
JP (2) JP6753933B2 (ko)
CN (2) CN116036284A (ko)
AU (7) AU2016369407B2 (ko)
CA (1) CA3007750A1 (ko)
CY (1) CY1120950T1 (ko)
DK (1) DK3298040T3 (ko)
ES (1) ES2692773T3 (ko)
GB (1) GB201522186D0 (ko)
HK (1) HK1254287A1 (ko)
HR (1) HRP20181692T1 (ko)
HU (1) HUE041433T2 (ko)
LT (1) LT3298040T (ko)
NZ (1) NZ744307A (ko)
PL (1) PL3298040T3 (ko)
PT (1) PT3298040T (ko)
RS (1) RS57894B1 (ko)
SG (2) SG11201804836RA (ko)
SI (1) SI3298040T1 (ko)
TR (1) TR201815415T4 (ko)
WO (1) WO2017103108A1 (ko)
ZA (1) ZA201803727B (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
AU2017378111A1 (en) * 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
MX2021008727A (es) 2019-01-21 2021-11-04 Singapore Health Serv Pte Ltd Tratamiento de la hepatotoxicidad.
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
AU2020268619A1 (en) 2019-05-03 2021-12-16 National University Of Singapore Treatment and prevention of metabolic diseases
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
US20210038584A1 (en) * 2019-08-05 2021-02-11 Novocure Gmbh Increasing Cancer Cells' Sensitivity to Tumor Treating Fields (TTFields) by Inhibiting IL11 Activity
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
JP2023537422A (ja) * 2020-08-13 2023-08-31 サンシャイン・レイク・ファーマ・カンパニー・リミテッド Ｉｌ－１１の抗体及びその使用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
US20240124572A1 (en) 2021-02-26 2024-04-18 Bayer Aktiengesellschaft INHIBITORS OF IL-11 OR IL-11Ra FOR USE IN THE TREATMENT OF ABNORMAL UTERINE BLEEDING
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
EP4448096A1 (en) 2021-12-16 2024-10-23 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease
CN115414346B (zh) * 2022-08-29 2023-09-29 湖南复瑞生物医药技术有限责任公司 一种应用胺碘酮构造肺纤维化模型的方法
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1493825A3 (en) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
AU717928B2 (en) 1994-12-22 2000-04-06 Genetics Institute, Llc Human interleukin-11 receptor
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
WO2000078336A1 (en) * 1999-06-21 2000-12-28 Genetics Institute, Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
WO2003049693A2 (en) 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
CA2498931A1 (en) 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
JP2007537716A (ja) 2003-12-16 2007-12-27 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼイション サイトカイン結合ドメイン
US20060019890A1 (en) 2004-01-15 2006-01-26 Kapoun Ann M Method for treating cardiac remodeling following myocardial injury
US20080300147A1 (en) 2004-03-26 2008-12-04 Nasser Chegini Detection and Treatment of Fibrotic Disorders
DK1630232T3 (da) 2004-08-27 2008-10-20 Conaris Res Inst Ag Optimerede nukleotidsekvenser kodende for sgp130
WO2007067602A1 (en) 2005-12-06 2007-06-14 Wyeth Interleukin-11 compositions and methods of use
MX352516B (es) 2006-07-05 2017-04-06 Fibrotech Therapeutics Pty Ltd Compuestos terapeuticos.
US8361966B2 (en) * 2006-10-27 2013-01-29 Osaka University Use of interleukin-11 as therapeutic agent for heart disease
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
ES2536877T3 (es) 2007-10-26 2015-05-29 Csl Limited Muteínas de citocina
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
CA2898618A1 (en) * 2013-02-07 2014-08-14 Csl Limited Il-11r binding proteins and uses thereof
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
AU2017378111A1 (en) 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
NL2020093B1 (en) 2017-12-15 2019-06-25 Stahl Int B V Process for producing aqueous polyurethane dispersions in a continuous manner; apparatus suitable for performing such a process; and products obtained by said process
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Also Published As

Publication number Publication date
US20180362637A1 (en) 2018-12-20
US10894827B2 (en) 2021-01-19
AU2016369407A1 (en) 2018-08-02
US10894826B2 (en) 2021-01-19
EP3428188A1 (en) 2019-01-16
CN108495861A (zh) 2018-09-04
US20180362639A1 (en) 2018-12-20
US10927169B2 (en) 2021-02-23
EP3431500A1 (en) 2019-01-23
US10106603B2 (en) 2018-10-23
WO2017103108A1 (en) 2017-06-22
US10822405B2 (en) 2020-11-03
EP3431498A1 (en) 2019-01-23
EP3298040A1 (en) 2018-03-28
ZA201803727B (en) 2019-03-27
US20180265579A1 (en) 2018-09-20
HUE041433T2 (hu) 2019-05-28
AU2018229485A1 (en) 2018-10-04
US20180362636A1 (en) 2018-12-20
US10899832B2 (en) 2021-01-26
PT3298040T (pt) 2018-11-13
ES2692773T3 (es) 2018-12-05
EP3431499A1 (en) 2019-01-23
RS57894B1 (sr) 2019-01-31
HRP20181692T1 (hr) 2018-12-14
US20180371078A1 (en) 2018-12-27
AU2018229487A1 (en) 2018-10-04
SI3298040T1 (sl) 2019-01-31
JP7102474B2 (ja) 2022-07-19
CN108495861B (zh) 2023-01-10
US10865240B2 (en) 2020-12-15
US10035852B2 (en) 2018-07-31
US20180362641A1 (en) 2018-12-20
US20180362638A1 (en) 2018-12-20
US10865241B2 (en) 2020-12-15
PL3298040T3 (pl) 2019-07-31
US10894825B2 (en) 2021-01-19
CY1120950T1 (el) 2019-12-11
DK3298040T3 (en) 2018-11-05
CN116036284A (zh) 2023-05-02
HK1254287A1 (zh) 2019-07-19
US10865239B2 (en) 2020-12-15
US11939374B2 (en) 2024-03-26
AU2018229487B2 (en) 2019-08-08
AU2018229484B2 (en) 2019-08-08
NZ744307A (en) 2019-03-29
TR201815415T4 (tr) 2018-11-21
AU2018229483B2 (en) 2019-08-08
KR20180097645A (ko) 2018-08-31
US20190002553A1 (en) 2019-01-03
AU2018229486A1 (en) 2018-10-04
LT3298040T (lt) 2018-12-10
US20170174759A1 (en) 2017-06-22
EP3428187A1 (en) 2019-01-16
US10870696B2 (en) 2020-12-22
AU2016369407B2 (en) 2018-09-13
US20210188962A1 (en) 2021-06-24
SG10201908380TA (en) 2019-11-28
US20180362634A1 (en) 2018-12-20
AU2018229484B9 (en) 2019-09-12
EP3428186A1 (en) 2019-01-16
AU2018229483A1 (en) 2018-10-04
AU2018229485B2 (en) 2019-08-08
CA3007750A1 (en) 2017-06-22
US20180362640A1 (en) 2018-12-20
AU2018229482B2 (en) 2019-08-08
US20180371077A1 (en) 2018-12-27
GB201522186D0 (en) 2016-01-27
JP2020189879A (ja) 2020-11-26
JP2019502689A (ja) 2019-01-31
JP6753933B2 (ja) 2020-09-09
US10889642B2 (en) 2021-01-12
EP3298040B1 (en) 2018-08-01
US20180362635A1 (en) 2018-12-20
AU2018229484A1 (en) 2018-10-04
AU2018229486B2 (en) 2019-08-08
AU2018229482A1 (en) 2018-10-04
US20180362633A1 (en) 2018-12-20
US10870697B2 (en) 2020-12-22

Similar Documents

Publication Publication Date Title
SG11201804836RA (en) Treatment of fibrosis
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201806845VA (en) Moisturizing compositions and uses thereof
SG11201810327XA (en) Single domain serum albumin binding protein
SG11201909949XA (en) Targeted immunotolerance
SG11201805137XA (en) Virus encoding an anti-tcr-complex antibody or fragment
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201901550WA (en) Method and apparatus for data processing
SG11201804132UA (en) Eif4-a-inhibiting compounds and methods related thereto
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201810485SA (en) Substituted carbonucleoside derivatives useful as anticancer agents
SG11201810522UA (en) Anti-cd40 antibodies and their uses
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806284TA (en) Low pressure separator having an internal divider and uses therefor
SG11201806400XA (en) Replicative transposon system
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201805204WA (en) Nicotine particle capsule
SG11201805001UA (en) Method of treating influenza a
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201811221XA (en) Imidazo[1,2-a]pyridine derivatives, methods for preparing the same and use thereof